valu inflect price initi perform
initi coverag perform rate
valu share rang believ compani begin
phase leverag platform diversifi pipelin engag commerci
valu creation time like valid rnai trim platform technolog
potenti applic multipl tissu type clinic stage pipelin option
pursu larg orphan indic recent fund balanc sheet
believ factor also appreci investor current trade
price stock offer balanc risk-reward next month may offer us
opportun assess clinic evid trim applic beyond hepatocyt
lung muscl indic gain clariti broader strategi
regul
platform technolog clinic valid liver modul hepatocyte-bas
target data impli high level target protein reduct hepatocyt lower
dose minim toxic liver use clinic valid await evid
clinic activ lung/muscles/solid tumor believ may repres
aro-aat posit aatd-liv diseas arwr lead asset
phase trial treat patient antitrypsin defici aatd
associ liver diseas could address unmet need orphan market
address us market opportun aatd genet condit
caus mutat gene encod
follow-on clinic asset present option clariti develop
level
lower triglycerid ldl-cholesterol may creat potenti valu inflect
opportun assum initi plan develop orphan
indic howev manag could opt address larger cardiovascular
condit may affect valu estim two asset
competit development dynam assum three lead product
first-to-market treatment respect orphan indic howev
note competit pipelin dynam may prove us aggress aro-aat
primari driver valuat lead aatd-liv diseas pipelin two
rnai therapi target clinic similarli aro-
also compet development clinic stage asset
partnership may drive valu manag time indic potenti
strateg partnership could present upsid valuat
also note stock recent experienc meaning momentum may
alreadi reflect valu
year price histori
medicin treat intract diseas
silenc
caus
use broad portfolio rna
chemistri effici mode
deliveri arrowhead therapi trigger
rna interfer mechan induc
knockdown target gene
gene
analyst certif import disclosur see disclosur
believ compani begin phase leverag
platform diversifi pipelin engag commerci
valu creation time like valid rnai
trim platform technolog potenti applic multipl
tissu type clinic stage pipelin option pursu
larg orphan indic strong balanc sheet
believ factor also appreci investor
current trade price stock offer balanc risk-
reward opportun next month may offer us
opportun assess clinic evid trim applic
beyond hepatocyt lung potenti muscl indic
gain clariti broader strategi includ
aro-aat launch probabl adjust patient
share grow outer year us eu
launch probabl adjust patient
share grow outer year us
launch probabl adjust patient
share grow hofh hofh outer year us
oper expens near term consist
 expens grow longer term includ
 run rate
initi phase data
phase data
phase data
preliminari phase data
aro-enac preliminari phase data
aro-aat open-label phase trial data
posit clinic readout aro-aat registration-en trial
posit phase clinic readout
clinic valid aro-enac aro-hsd
aro-aat safeti efficaci concern
neg clinic readout phase
failur obtain mileston
arrowhead inc clinical-stag biotechnolog
compani proprietari rna interfer rnai platform technolog call target
rnai molecul trim trim platform basi arwr pipelin drug
treat genet diseas character aberr product intracellular protein
rnai process gene silenc messeng rna mrna encod
specif protein target degrad prevent translat thu arrest
synthesi protein interest silenc specif gene limiting/elimin
product specif protein arwr therapeut agent target diseas caus
current develop sever rnai therapi across wide rang indic
independ via collabor partnership janssen
manag highlight numer clinic mileston exhibit
import catalyst view phase readout aro-
hypertriglyceridemia dyslipidemia respect top-lin readout
phase open-label studi patient liver diseas associ
potenti data per manag earn confer call
asset indic liver diseaseliverpre-ctaaro-enaccyst cell indicationpotenti readyliv diseasecta readyren cell carcinomacta expect us diseaseiniti phase readycyst fibrosiscta expect us data data readyliv diseasephas diseasephas initi readyren cell carcinomapreliminari phase readycyst fibrosispreliminari phase liver diseasepotenti data arrowhead pharmaceut
arwr target rnai molecul trim platform technolog clinic valid
target liver modul number hepatocyte-bas target also
gener anim model evid lung solid tumor target
trim platform consist heavili modifi sirna small interf rna molecul
exhibit demonstr abil target protein hepatocyt potenti
cell type organ liver detail modif
proprietari broadli includ high affin target ligand improv tissu specif
number alter rna chemistri improv stabil manag claim
modif provid mean achiev rel long period protein
knockdown potenti enabl longer durat therapeut benefit per episod
custom compon trim platform target specif mrna
select certain nucleotid sequenc tissu interest affix target-bas
ligand optim knockdown durat effect util particular modif
stabil chemistri
view ideal rnai platform therapeut applic lead high
level target protein reduct specif cell low toxic eas
administr includ minim dose achiev platform
sirna potenc potenc degre protein reduct could depend
abil sirna target specif locat mrna sequenc
lead maximum mrna degred result minim protein
sirna specif specif bind correct mrna minim off-
target effect import minimize/elimin unwant reduct
protein similar rna sequenc
sirna stabil sirna broken enzym blood remov
immun system excret renal filtrat chemic modif
rnai molecul may maintain high level sirna prevent
deliveri right tissues/cel sirna difficulti pass
cell membran improv develop chemic vehicl allow
permeat sirna cell target specif cell type may
achiev attach sirna receptor ligand antibodi
recogn cell interest
minim dose minimum dose highli prefer determin four
characterist especi high sirna stabil toxic immun
respons may also reduc minim dose
data earli clinic trial aro-aat suggest
arwr rnai platform robust proprietari modif may
value-enhanc specif note
high level target protein reduct hepatocyt asset target
protein liver may lead larg reduct greater target protein
blood serum exhibit
number dose requir singl dose appear maintain protein reduct
minim toxic note evid seriou advers event relat
thrombocytopenia renal function chang liver toxic measur alt enzym
concentr blood lower placebo inject site reaction
report may associ sirna-bas therapi exhibit
exhibit reduct target protein blood serum
data follow trial readout phase normal healthi volunt nhv singl dose studi present aasld
novemb aha novemb aha novemb respect
calcium oxal crystal urin
exhibit see follow page profil arwr trim platform along select list
rnai technolog platform manag claim arwr trim platform offer
simplifi manufactur
multipl rout
administr abil target sever tissu type improv safeti reduc
risk intracellular build-up less metabolit smaller/simpl
molecul await addit inform aspect pipelin matur
aro-aat arwr lead asset phase trial treat patient antitrypsin
deficiency-associ liver diseas could address unmet need orphan diseas
market estim could north global sale exhibit aatd
genet condit caus mutat gene encod alpha-
antitrypsin protein aatd-associ liver diseas proteinopathi diseas
result abnorm synthesi fold protein deposit cell
tissu result proteotox impair cellular function aggreg
misfold protein preliminarili character address market opportun
includ patient aatd caus homozyg express specif mutat
call z-mutat also exhibit stage liver fibrosi
exhibit preliminari market opportun estim aatd liver diseas
base us preval eu preval serr
includ patient may yet diagnos aatd
preval liver diseas base data swedish pizz individu tanash
preval clinic signific liver fibrosi base data north american pizz individu clark
base onpattro annual price per year us discount eu
market opportun estim
oppenheim research us censu bureau journal intern medicin de serr journal hepatolog clark
journal gastroenterolog tanash pricerx
 advers renal function thryombocytopenia alt inject reaction pizz preval pizz liver liver fibrosi stage carrier liver diseas fibrosi stage wac per patient per gross-to-net price per patient per aatd-associ liver diseas market opportun perform na
exhibit overview clinic stage rnai platform
product target less advanc program includ mrna untransl region hbv mrna
compani plan advanc program
subsidiari pharma sa
meet primari endpoint
companymarket cap platform nametarget methodtargetorgantarget proteinclaim modificationmost advanc assetindicationdevelop lung solid tumorsaat high specificity- minim liver diseasephas stabil conjugate- increas specificity- reduc immun stimulation- enhanc cellular delivery- improv risc actvityonpattrohereditari attr amyloidosismarketedintravenousescgalnacliverthrombin hepat glycol oxidas greater durat potenc sc platformfitusiraninclisiranlumasiranvutrisiranhemophilia bleed disordershypercholesterolemiaprimari hyperoxaluria type amyloidosisphas nanoparticl technologylipid nanoparticleliverhbv- wide adopt rnai deliveri technolog date- protect potent rnai trigger distribut rapidli efficiently- releas insid cell- minim immunotox undesir side conjug deliveri technologygalnacliverhbv hbsag- proprietari n-acetylgalactosamin galnac conjug technolog enabl subcutan deliveri rnai therapeut oxidase- subcutan deliv long durat action- high target specificity- high therapeut indexdcr-phxcprimari hyperoxaluriaphas rnaidirect inject tumorvari tumorsfurin- gene introduc one knockdown protein second overexpress differ protein- shrna break mrna two mechan henc improv knockdownvigilew sarcomaphas rnaundisclosedctgf- spontan cellular uptak sd-rxrna without need deliveri vehicl potent stabl specific- demonstr safe activ clinic scar follow surgeryphas caspas effici specif sirna guid strand load risc- reduc seed-medi off-target effects- improv protect breakdown reduc elimin immunostimulatori effects- improv product cellular uptak absenc transfect reagents- prolong tissu graft functionnon arterit anterior ischem optic neuropathyphas intravitrealsilenseedprivatelod polym matrix sirnaundisclosedsolid tumorskras- ductal adenocarcinomaphas nanoparticl pnp undisclosedtumor use chemic synthes rnai trigger sirna deliv target cell proprietari peptid nanoparticl pnp skin cancer hypertroph scar reductionphas undisclosedtivanisiran diseasephas eye drop
aro-aat lead aatd pipelin
aro-aat sirna-bas therapi target express mutant
liver common disease-caus variant gene known
 mutat lead misfold protein accumul liver cell z-aat
accummul caus liver diseas person inherit two copi
mutat referr pizz target patient popul aro-aat
intend prevent z-aat accumul allow z-aat clearanc ultim
prevent and/or reduc liver fibrosi theoret reduc product inflammatori
mutant protein could halt progress liver diseas potenti allow
regener repair independ studi valid target preclin
mous model demonstr liver diseas stabil revers liver diseas
long-term treatment prevent liver diseas young
present therapi develop treat aatd-associ
liver diseas exhibit note aro-aat ahead other clinic develop
may competit advantag trial enrol given nich patient
popul low rate diagnosi
exhibit competit pipelin aatd
phase data demonstr serum reduct exhibit initi
potenti registration-en phase studi sequoia includ initi dose
select portion subsequ evalu efficaci vs placebo optim dose
arrowheadalnylamdicernawashu xr carbamazepin platformgalnac ligand sirnaesc galnac-conjug deliveri rnai galxc rnai technolog platformsmal molecul z- autophagy/degredationstudi target patient profil liver fibrosiszz type liver zz sz phenotypedevelop stagephas dosingsubcutaneoussubcutaneoussubcutaneous oral tabletsdos frequencyquarterli less frequentmonthli dose dailycatalyst timingmay complet jun complet dec complet perform na
through/at end studi biopsi day /- day last part dose
separ phase design assess histolog chang liver
variou timepoint vari dose schedul follow open label extens
cohort baselin week cohort baselin week extens baselin week
estim enrol inclus criteriadiagnosi pizz patient liver biopsi screen indic liver fibrosispart apart bdesign timelinefirst patient random treatment placebotreat administ day undergo liver biopsi pre-dos day base part resultspart enrol patient new patient receiv six nine quarterli dose respect part select dose levelpati undergo liver biopsydosingsubcutan aro- solut inject aro- solut inject select dose tbdprimari endpoint chang baselin solubl liver z- insolubl liver z- chang baselin serum particip possibl probabl relat particip achiev improv histolog grade scale associ liver diseas worsen liver fibrosi base ishak enrol inclus criteriadiagnosi ddesign timelineon-studi stage cohort begin month follow cohort month midway cohort label extens option enrol year extens follow on-studi stagebiopsi baselin week cohort week cohort week open label subcutan aro- solut inject cohort dose day week dose day week baselin time histolog liver diseas activ scale arrowhead pharmaceut
base medic literatur review estim preval pizz mutat
us eu pizz mutant
develop aatd progress stage liver fibrosi target commerci market
howev aatd may underdiagnos studi publish estim
diagnosi rate averag delay diagnosi
develop aro- d-associ liver diseas lead
diseas lung liver aatd affect lung liver differ
mechan exhibit mutat two effect mutant protein lose
normal abil function mutant protein misfold form aggreg
relat lung diseas result lack function protein level
liver diseas result directli aggreg
exhibit liver diseas defici patient
liver mutant misfold form protein retain hepatocyt
aggreg globul lead hepat fibrosi liver diseas chronic
hepat cirrhosi hepatocellular carcinoma studi publish
estim misfold protein retain
aatd-associ lung diseas result low level function protein
inhibitor neutrophil elastas enzym releas white blood cell fight
infect reduc amount lead uninhibit neutrophil proteas
destroy lung tissu result emphysema chronic obstruct pulmonari diseas
undertr
aatd-associ liver diseas identifi prior signific liver damag dietari
modif hepat vaccin recommend manag diseas progress
howev believ signific unmet need among therapeut altern
avail manag patient effect effect intervent liver
transplant typic use end stage liver diseas patient approxim
pediatr adult liver transplant result aatd-associ liver
diseas accord expert overal adult children aatd-associ
liver diseas appear excel surviv post-liv
bentley philip organ tissu transplant cost estim discuss milliman inc
recent report phase trial data two asset
assess safeti primari endpoint pharmacokinetics/pharmacodynam
secondari endpoint studi includ healthi adult patient sever
hypertriglyceridemia includ famili chylomicronemia syndrom fc aro-
studi patient dyslipidemia studi
await tg reduct stat fc
sirna design target reduc express
protein regul triglycerid tg level elev tg level
independ risk factor cardiovascular diseas sever elev tg level occur
patient fc result potenti fatal acut pancreat
recurr acut pancreat occur fc patient associ
mortal rate fc patient subgroup sever
complic pancreat necrosi infect multipl organ
protein synthes liver key regul tg metabol
compon triglycerid rich lipoprotein trl low-dens lipoprotein
vldl high-dens lipoprotein hdl chylomicron
multipl mechan affect tg level includ
inhibit lipoprotein lipas key enzym drive lipoprotein hydrolysi
 valdivielso ramirez-bueno ewald current knowledg hypertriglyceridem pancreat eur intern
diagnosi age diagnosisvari diagnosedgener year age pediatr year adult estim base liver standard care soc liver transplantefficaci socchildren surviv yearsadult surviv limitationsrisk associ liver transplantsaverag cost careliv transplant transplant per year follow arrowhead pharmaceut
promot hepat vldl secret and/or chylomicron format suppress
clearanc trl remnant product lipoprotein lipas
healthi volunt singl dose led mean
maximum reduct mean maximum reduct tg
week mean reduct tg serum level respect
exhibit serum impact human tg
trial singl dose led mean maximum serum
ldl-c reduct dose mean maximum serum hdl-c
chang dose exhibit one ae moder transient alt
elev eight mild local inject site reaction occur
exhibit serum impact human ldl-c hdl-c
reduct tg ldl-c level observ nhv promis difficult
predict like level reduct fc patient base data tg level
afflict person higher healthi person assum
therapeut altern becom avail like even modest reduct tg
level may therapeut accept
tg ldl-c reduct evid
sirna-bas therapi target express angiopoietin-lik
protein reduct level protein lead lower level
triglycerid ldl-cholesterol blood major risk factor atherosclerosi
cardiovascular diseas
 sack crucial role apolipoprotein c-iii apob lipoprotein metabol normolipidemia
protein exclus produc liver primari action
inhibit lipoprotein lipas lpl endotheli lipas enzym respons break
circul triglycerid ldl-c respect henc reduc
express lead lower level
hofh homozyg famili hypercholesterolemia hefh heterozyg famili
hypercholesterolemia inherit disord lipoprotein metabol character
mark elev low densiti lipoprotein cholesterol ldl-c xanthomata
prematur cardiovascular diseas cholesterol level increas typic much
sever hofh although genet heterogen often caus mutat
 gene encod
phase data healthi volunt show singl inject
result reduct serum express
inject led reduct tg level exhibit
singl inject led mean maximum ldl-c
reduct mean maximum hdl-c reduct exhibit
moder transient alt elev one mild local inject site reaction occur
exhibit serum impact human tg
exhibit serum impact human ldl-c hdl-c
updat data phase trial present aha demonstr durabl serum
reduct week subject receiv second dose
week experienc ldl-c reduct exhibit
exhibit serum impact multipl dose
assum base current clinic trial protocol would develop
orphan indic fc hofh/hefh
preliminarili estim address market opportun two asset
respect exhibit see follow page note manag
could opt address broader indic may affect valu estim
exhibit preliminari market opportun estim fc
market opportun estim
base onpattro annual price per year us discount eu
oppenheim research us censu bureau kastelein nord shah journal american colleg cardiolog
exhibit preliminari market opportun estim fh
consid patient achiev ldl-c target despit statin use rosenson aha journal defesch
journal clinic lipidolog
assum price pariti agent
estim hofh market opportun region
clinicoeconom outcom research zamora journal clinic lipidolog european atherosclerosi societi
target valuat rang base discount cash flow dcf analysi
note calendar base septemb fiscal year end
dcf after-tax work cash flow per share discount rate current valu valu valu cash valu rate growth rate perform na
model ten year sale three pipelin asset clinic mileston
payment aro-hbv exhibit assumpt underli valuat
rang
aro-aat launch probabl adjust patient share
address patient popul launch grow outer year
launch probabl adjust patient share
launch grow outer year us
launch probabl adjust patient share
launch grow outer year hofh patient share
launch year grow outer year hefh us eu
model gross margin wholli own asset jnj-
oper expens near term consist expens
grow longer term includ sale market expens
use net oper loss nol balanc carri forward off-set
annual taxabl incom use tax rate thereaft
discount cash flow year-end discount rate
believ approxim compani weight averag cost capit base
risk-fre rate expect market return beta per
termin valu growth rate valu attribut termin
assum key driver valuat aro-aat us
first market treatment respect orphan indic
howev given competit development dynam exhibit compani
orphan design obtain approv ahead indic may
delay approv arwr asset durat exclus period year
us year eu meaning affect revenu assumpt
indic recipi fda orphan drug design
sever class drug approv famili hypercholesterolemia includ statin bile-acid-bind resin cholestoerol absorpt inhibitor inject medic mani
patient current treatment inadequ
theoret estim neg impact valuat rang aro-aat
revenu lower current estim exhibit
exhibit aro-aat downsid valuat
designationyesyesyesind pursuedaatdfcshofh/hefhdevelop stagephas pipelin pipelin phase phase waylivra market eu phase evinacumab pre-bla file phase /pfe market casedownsidearo-aat share market valuat revenu downsid valuat perform na
aro-aat lead pack competitor close behind
compani alnylam dicerna drug clinic trial target
defici design reduc mutant protein express
alnylam sirna-bas drug develop use compani new esc
rnai platform current phase trial evalu agent nhv
patient pizz type aatd-associ liver diseas primari complet june
accord clinicaltri gov claim esc platform improv durat
potenc knockdown reduc toxic evidenc first-gener aln-
reduct level day transient liver enzym
elev last day higher dose exhibit
exhibit phase studi previou version
dicerna partnership boehringer-ingelheim initi phase trial eu
evalu safeti toler pharmacokinet pharmacodynam
healthi volunt patient aatd-associ liver diseas
ions/akca waylivra volanesorsen approv eu fc file
approv us howev receiv complet respons letter august
potenti refil us subsequ approv may neg impact
estim revenu opportun arwr fc novemb
manag note hope re-fil us
compani disclos reason waylivra note nine
patient discontinu phase trial due advers event treatment
includ two case grade thrombocytopenia three case lesser grade
thrombocytopenia well inject site reaction fatigu fatigu chill
sweat gener erythema waylivra label eu point safeti
risk provid platelet monitor dose- adjust guidelin
ions/akca also develop next-gener akcea-apociii-lrx phase
trial patient hypertriglyceridemia establish cardiovascular diseas
anticip data earli note trial specif includ fc patient
target
akca/pf regeneron also product develop target
safeti efficaci
novemb licens akcea phase
patient
hypertriglyceridemia type diabet nafld on-going part trial patient
receiv one three dose placebo assess
month anticip initi phase result
studi
august announc top-lin result phase studi evinacumab
monoclon antibodi
administr evinacumab addit lipid-low therapi decreas ldl-
 week plan regulatori submiss
hofh patient monthli
inclisiran sirna agent develop mdco recent acquir nv
target mrna also assess patient hefh phase
trial hefh patient receiv subcutan inject inclisiran day
demonstr reduct ldl-c versu increas placebo
day inclisiran target present anoth
treatment option intend reduc ldl-c
mileston contribut bake valuat
model mileston probabl adjust valu formerli
aro-hbv phase trial hepat given time term
mileston payment disclos simplist assum three equal
payment posit phase data posit phase data regulatori
approv probabl adjust likelihood success phase exhibit
oppenheim research compani materi clinic develop success rate investig drug hay natur
estim neg impact valuat rang mileston
realiz posit impact realiz within estim
milestoneprob adjustmentp impact remain up-front payment reef phase initiationn/a alreadi combinedphas success elig mileston revenu success elig mileston revenu elig mileston revenu perform na
partnership may provid upsid valuat
comment likelihood transact futur note
stock experienc meaning upward momentum recent may reflect
investor enthusiasm near-term partnership and/or acquisit announc
oppenheim research factset compani materi note result view indic futur perform
compani materi douglass given brother bruce given
manag teamprior experience/educationchristoph anzalon ph dbenet group founder chief execut offic presidentgalway partner llc partnersmithsonian institut postdoctor fellowph biolog univers california lo angelesb govern lawrenc universitybruc given icon plc chairman board directorschief oper offic head dencys presid obruc given consult presidentcalando inc directorleonardo biosystem inc oclin fellow harvard medic school/brigham women hospitalm honor univers chicago pritzker school medicineb colorado state universityken myszkowski broadwind corpor controllerchief financi officerepcor util inc controllernanoink controllerdelphion controllerm univers chicago booth school businessbachelor univers illinoisdouglass given ph capit partner manag partnerchairman board directorsinvestor bay citi capit gener partnerm wharton school univers pennsylvania research fellow massachusett gener hospit harvard medic schoolintern medicin clinic fellowship massachusett gener hospit harvard medic schoolm /ph univers chicago pritzker school medicin perform na
stock price compani mention report
chang valu deriv
interest incom expens
revenu
earn model balanc sheet next page opco research compani report
earn model balanc sheet next page opco research compani report
accru payrol benefit
defer rent net current portion
defer revenu net current portion
note payabl net current portion
total liabil sharehold equiti
cash equival
